Robert Andrew Chambers1, Alena M Sentir, Eric A Engleman. 1. Institute of Psychiatric Research, Department of Psychiatry, Indiana University School of Medicine, Indianapolis, 46202, USA. robchamb@iupui.edu
Abstract
RATIONAL: Exposing animal models of mental illness to addictive drugs provides an approach to understanding the neural etiology of dual diagnosis disorders. Previous studies have shown that neonatal ventral hippocampal lesions (NVHL) in rats produce features of both schizophrenia and addiction vulnerability. OBJECTIVE: This study investigated ventral and dorsal striatal dopamine (DA) efflux in NVHL rats combined with behavioral sensitization to cocaine. METHODS: Adult NVHL vs. SHAM-operated rats underwent a 5-day injection series of cocaine (15 mg/kg/day) vs. saline. One week later, rats were cannulated in nucleus accumbens SHELL, CORE, or caudate-putamen. Another week later, in vivo microdialysis sampled DA during locomotor testing in which a single cocaine injection (15 mg/kg) was delivered. RESULTS: NVHLs and cocaine history significantly increased behavioral activation approximately 2-fold over SHAM-saline history rats. DA efflux curves corresponded time dependently with the cocaine injection and locomotor curves and varied significantly by striatal region: Baseline DA levels increased 5-fold while cocaine-stimulated DA efflux decreased by half across a ventral to dorsal striatal gradient. However, NVHLs, prior cocaine history, and individual differences in behavior were not underpinned by differential DA efflux overall or within any striatal region. CONCLUSION: Differences in ventral/dorsal striatal DA efflux are not present in and are not required for producing differential levels of acute cocaine-induced behavioral activation in NVHLs with and without a behaviorally sensitizing cocaine history. These findings suggest other neurotransmitter systems, and alterations in striatal network function post-synaptic to DA transmission are more important to understanding the interactive effects of addictive drugs and mental illness.
RATIONAL: Exposing animal models of mental illness to addictive drugs provides an approach to understanding the neural etiology of dual diagnosis disorders. Previous studies have shown that neonatal ventral hippocampal lesions (NVHL) in rats produce features of both schizophrenia and addiction vulnerability. OBJECTIVE: This study investigated ventral and dorsal striatal dopamine (DA) efflux in NVHL rats combined with behavioral sensitization to cocaine. METHODS: Adult NVHL vs. SHAM-operated rats underwent a 5-day injection series of cocaine (15 mg/kg/day) vs. saline. One week later, rats were cannulated in nucleus accumbens SHELL, CORE, or caudate-putamen. Another week later, in vivo microdialysis sampled DA during locomotor testing in which a single cocaine injection (15 mg/kg) was delivered. RESULTS: NVHLs and cocaine history significantly increased behavioral activation approximately 2-fold over SHAM-saline history rats. DA efflux curves corresponded time dependently with the cocaine injection and locomotor curves and varied significantly by striatal region: Baseline DA levels increased 5-fold while cocaine-stimulated DA efflux decreased by half across a ventral to dorsal striatal gradient. However, NVHLs, prior cocaine history, and individual differences in behavior were not underpinned by differential DA efflux overall or within any striatal region. CONCLUSION: Differences in ventral/dorsal striatal DA efflux are not present in and are not required for producing differential levels of acute cocaine-induced behavioral activation in NVHLs with and without a behaviorally sensitizing cocaine history. These findings suggest other neurotransmitter systems, and alterations in striatal network function post-synaptic to DA transmission are more important to understanding the interactive effects of addictive drugs and mental illness.
Authors: Jenifer L Vohs; R Andrew Chambers; Giri P Krishnan; Brian F O'Donnell; Sarah Berg; Sandra L Morzorati Journal: Int J Neuropsychopharmacol Date: 2009-07-23 Impact factor: 5.176
Authors: Rubén Antonio Vázquez-Roque; Brenda Ramos; Carolina Tecuatl; Ismael Juárez; Anthony Adame; Fidel de la Cruz; Sergio Zamudio; Raúl Mena; Edward Rockenstein; Eliezer Masliah; Gonzalo Flores Journal: J Neurosci Res Date: 2011-09-19 Impact factor: 4.164
Authors: Eduardo Blanco; Ainhoa Bilbao; María Jesús Luque-Rojas; Ana Palomino; Francisco J Bermúdez-Silva; Juan Suárez; Luis J Santín; Guillermo Estivill-Torrús; Antonia Gutiérrez; José Angel Campos-Sandoval; Francisco J Alonso-Carrión; Javier Márquez; Fernando Rodríguez de Fonseca Journal: Psychopharmacology (Berl) Date: 2011-09-02 Impact factor: 4.530
Authors: Jibran Y Khokhar; Lucas L Dwiel; Angela M Henricks; Wilder T Doucette; Alan I Green Journal: Schizophr Res Date: 2017-04-14 Impact factor: 4.939
Authors: R A Chambers; J N McClintick; A M Sentir; S A Berg; M Runyan; K H Choi; H J Edenberg Journal: Genes Brain Behav Date: 2013-06-22 Impact factor: 3.449
Authors: Christopher C Lapish; Kee-Chan Ahn; R Andrew Chambers; Donovan M Ashby; Soyon Ahn; Anthony G Phillips Journal: Neuropsychopharmacology Date: 2014-01-30 Impact factor: 7.853
Authors: Sarah A Berg; Alena M Sentir; Benjamin S Cooley; Eric A Engleman; R Andrew Chambers Journal: Addict Biol Date: 2013-08-06 Impact factor: 4.280